AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06133985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costovertebral mobilizations + Conventional PT
Description: Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
Study NCT06133985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
Study NCT05013294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: Text messages through a basic phone or smart phone
Study NCT05013294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Text messages through a basic phone or smart phone
Study NCT05820646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boswellia Sacra
Description: 1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days
Study NCT05820646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Boswellia Sacra
Description: 1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days
Study NCT06122246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)
Description: Participants will receive the additional support of a Community Health Worker (CHW).
Study NCT06122246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Blood Pressure (BP) Management Program (RBPM)
Description: Participants will receive a medical model of remote BP management (RBPM).
Study NCT06122246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Blood Pressure (BP) Management Program (RBPM)
Description: Participants will receive a medical model of remote BP management (RBPM).
Study NCT06508970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental RAM-based virtual reality glasses
Description: RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)
Study NCT06508970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pre-post test
Description: Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
Study NCT06508970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-post test
Description: Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
Study NCT05263544 — intervention group
Intervention type: OTHER
Intervention: measuring uterocervical angle and uterine dimensions
Description: in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
Study NCT04231032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronous dual chamber pacing (DOO) with paced ventricular activation
Description: Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
Study NCT04231032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Asynchronous atrial pacing (AOO) with intrinsic ventricular activation
Description: Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
Study NCT04673669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Posterior tibial tendon strength mesure
Description: Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
Study NCT05957848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release Oral Tablet
Description: Target dose 4 mg daily
Study NCT05957848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential withdrawal
Description: 4-14 days in residential withdrawal treatment
Study NCT05957848 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Residential withdrawal
Description: 4-14 days in residential withdrawal treatment
Study NCT05957848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement with alcohol and other drug services
Description: Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
Study NCT05957848 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Engagement with alcohol and other drug services
Description: Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
Study NCT05957848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken daily
Study NCT04843943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg IV Q3W D1
Study NCT04843943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar
Description: Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
Study NCT06382961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
Study NCT06382961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil injection
Description: 3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
Study NCT03307018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative systematic bronchial aspiration.
Description: Postoperative flexible bronchoscopy and systematic bronchial aspiration.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrozumab
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05725200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
Study NCT05876988 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chinese acupuncture
Description: Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment.
Study NCT05876988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chinese acupuncture
Description: Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment.
Study NCT05581355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal breathing training
Description: In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
Study NCT04563611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turkish Get-up exercise
Description: TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
Study NCT04563611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Askling L-Protocol
Description: he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
Study NCT06790732 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Patients received sham PENG block (just 1mL saline).
Study NCT06790732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexamethasone
Description: Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
Study NCT05797818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene Blue Only
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene Blue (0.01%) + 4 minutes of light treatment
Study NCT05797818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate Only
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment
Study NCT05797818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene Blue + Chlorhexidine Gluconate
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment
Study NCT05797818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Only
Description: All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- 4 minutes of light treatment only
Study NCT04563611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise
Description: To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
Study NCT04563611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
Study NCT04884529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chair-yoga program
Description: 8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
Study NCT05281068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
Study NCT05281068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Oral danazol (200 mg twice daily) for 12 weeks.
Study NCT05281068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Oral danazol (200 mg twice daily) for 12 weeks.
Study NCT05373316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated MR-guided radiotherapy boost
Description: External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
Study NCT06120933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hair Nutra Growth Supplement & Hair Nutra Boost Supplement
Description: Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water.
Study NCT06120933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hair Nutra Growth
Description: From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water.
Study NCT04487938 — intervention group
Intervention type: OTHER
Intervention: No intervention utilised
Description: No intervention utilised
Study NCT05869266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: professional fitting vs. self fitting
Description: Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
Study NCT05445336 — intervention group
Intervention type: BEHAVIORAL
Intervention: PREVENT Program
Description: PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
Study NCT05808023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP powder reintroduction
Description: The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
Study NCT05333640 — intervention group
Intervention type: DEVICE
Intervention: Sirolimus Drug Coated Balloon
Description: AVFs treated with SDCB
Study NCT05333640 — intervention group
Intervention type: DEVICE
Intervention: Paclitaxel Drug Coated Balloon
Description: AVFs treated with PDCB
Study NCT04731922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510
Description: TAK-510 solution.
Study NCT04731922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510 Placebo
Description: TAK-510 placebo-matching solution.
Study NCT06792474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine in Saline
Description: Lidocaine infusion 1.5 mg/kg/hr
Study NCT06792474 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion
Study NCT05878691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 54276
Description: Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm.
Study NCT05878691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 54276 + Pembrolizumab
Description: Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm.